A Circulating Biomarker-based Framework for Diagnosis of Hepatocellular Carcinoma in a Clinically Relevant Model of Non-alcoholic Steatohepatitis; An OAD to NASH
Authors:
** Zhou,
Anne Hwang,
Christopher Shi,
Edward Zhu,
Farha Naaz,
Zainab Rasheed,
Michelle Liu,
Lindsey S. Jung,
**gsong Li,
Kai Jiang,
Latha Paka,
Michael A. Yamin,
Itzhak D. Goldberg,
Prakash Narayan
Abstract:
Although cirrhosis is a key risk factor for the development of hepatocellular carcinoma (HCC), mounting evidence indicates that in a subset of patients presenting with non-alcoholic steatohepatitis (NASH), HCC manifests in the absence of cirrhosis. Given the sheer size of the non-alcoholic fatty liver disease (NAFLD) epidemic, and the dismal prognosis associated with late-stage primary liver cance…
▽ More
Although cirrhosis is a key risk factor for the development of hepatocellular carcinoma (HCC), mounting evidence indicates that in a subset of patients presenting with non-alcoholic steatohepatitis (NASH), HCC manifests in the absence of cirrhosis. Given the sheer size of the non-alcoholic fatty liver disease (NAFLD) epidemic, and the dismal prognosis associated with late-stage primary liver cancer, there is an urgent need for HCC surveillance in the NASH patient. In the present study, adult male mice randomized to control diet or a fast food diet (FFD) were followed for up to 14 mo and serum level of a panel of HCC-relevant biomarkers was compared with liver biopsies at 3 and 14 mo. Both NAFLD Activity Score (NAS) and hepatic hydroxyproline content were elevated at 3 and 14 mo on FFD. Picrosirius red staining of liver sections revealed a filigree pattern of fibrillar collagen deposition with no cirrhosis at 14 mo on FFD. Nevertheless, 46% of animals bore one or more tumors on their livers confirmed as HCC in hematoxylin-eosin-stained liver sections. Receiver operating characteristic (ROC) curves analysis for serum levels of the HCC biomarkers osteopontin (OPN), alpha-fetoprotein (AFP) and Dickkopf-1 (DKK1) returned concordance-statistic/area under ROC curve of > 0.89. These data suggest that serum levels of OPN (threshold, 218 ng/mL; sensitivity, 82%; specificity, 86%), AFP (136 ng/mL; 91%; 97%) and DKK1 (2.4 ng/mL; 82%; 81%) are diagnostic for HCC in a clinically relevant model of NASH
△ Less
Submitted 19 November, 2017; v1 submitted 2 October, 2017;
originally announced October 2017.
Renal Parenchymal Area and Kidney Collagen Content
Authors:
Jake A. Nieto,
Janice Zhu,
Bin Duan,
**gsong Li,
** Zhou,
Latha Paka,
Michael A. Yamin,
Itzhak D. Goldberg,
Prakash Narayan
Abstract:
The extent of renal scarring in chronic kidney disease (CKD) can only be ascertained by highly invasive, painful and sometimes risky tissue biopsy. Interestingly, CKD-related abnormalities in kidney size can often be visualized using ultrasound. Nevertheless, not only does the ellipsoid formula used today underestimate true renal size but also the relation governing renal size and collagen content…
▽ More
The extent of renal scarring in chronic kidney disease (CKD) can only be ascertained by highly invasive, painful and sometimes risky tissue biopsy. Interestingly, CKD-related abnormalities in kidney size can often be visualized using ultrasound. Nevertheless, not only does the ellipsoid formula used today underestimate true renal size but also the relation governing renal size and collagen content remains unclear. We used coronal kidney sections from healthy mice and mice with renal disease to develop a new technique for estimating the renal parenchymal area. While treating the kidney as an ellipse with the major axis the polar distance, this technique involves extending the minor axis into the renal pelvis. The calculated renal parenchymal area is remarkably similar to the measured area. Biochemically determined kidney collagen content revealed a strong and positive correlation with the calculated renal parenchymal area. The extent of renal scarring, i.e. kidney collagen content, can now be computed by making just two renal axial measurements which can easily be accomplished via noninvasive imaging of this organ.
△ Less
Submitted 10 November, 2016; v1 submitted 7 November, 2016;
originally announced November 2016.
